Elke Dworatzek - Publications

Plain language summary examining clinical event related costs associated with changing medication from apixaban to rivaroxaban in people with non-valvular atrial fibrillation in the USA and Germany.

Journal: Journal of medical economics

Published: February 23, 2026

Transforming atrial fibrillation management by targeting comorbidities and reducing atrial fibrillation burden: the 10th AFNET/EHRA consensus conference.

Journal: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology

Published: November 28, 2025

Cost-effectiveness and budget impact analysis of switching from apixaban to rivaroxaban treatment among patients with nonvalvular atrial fibrillation in a German healthcare setting.

Journal: Journal of comparative effectiveness research

Published: May 21, 2025

Decision model to evaluate the cost of clinical events associated with switching from apixaban to rivaroxaban among patients with non-valvular atrial fibrillation in the United States and Germany.

Journal: Journal of medical economics

Published: January 17, 2025

Cultivating Excellence: Future-Proofing Medical Affairs with Tailored Talent Programs.

Journal: Pharmaceutical medicine

Published: July 15, 2024

Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference.

Journal: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology

Published: December 22, 2023